Expression of TIGIT and FCRL3 is Altered in T Cells from Patients with Distinct Patterns of Chronic Autoimmune Thyroiditis

Štefanić, Mario; Tokić, Stana; Suver-Stević, Mirjana; Glavaš‐Obrovac, Ljubica

doi:10.1055/a-0597-8948

Cited by 8 publications

(2 citation statements)

References 48 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As existing research have confirmed that abnormalities in function or number of Tregs are a feature of autoimmune diseases, to date, numerous animal models and human studies have verified the upregulation of TIGIT + Tregs in various autoimmune diseases, such as NOD mouse islets, type1 diabetes (T1D) patients, 92,93 thyroiditis, 94,95 aplastic anemia (AA), 96 multiple sclerosis (MS) 97 and noninfectious uveitis, 98 and may be proportional to disease severity.…”

Section: Tigit Expression In Autoimmune Diseasesmentioning

confidence: 99%

The landscape of TIGIT target and clinical application in diseases

et al. 2022

View full text Add to dashboard Cite

Immune checkpoint blockade has dramatically altered the concept of cancer therapeutics over the past few years. Beyond the existing classical pathways, novel immune checkpoints, such as T‐cell immunoglobulin and immunoreceptor tyrosine‐based inhibitory motif (ITIM) structural domain (TIGIT), have also emerged in recent years and have promising therapeutic potential. Recent researches have provided ample evidence that TIGIT is extensively involved in various cancerous and noncancerous diseases such as chronic inflammation, autoimmune diseases, abnormal pregnancy status, and most recently coronavirus disease 2019. In contrast to the programmed cell death receptor 1 pathway which primarily affects T‐cell function, targeting TIGIT pathway regulates multiple types of immunocytes but has fewer immune‐related adverse events. Owing to its unique advantages and extensive involvement in diseases, extensive clinical trials blockade TIGIT or combine it with other targets are ongoing, and numerous phase II clinical trials have already seen promising results. In this review, we summarized the existing research on TIGIT in various diseases and discussed the perspective and challenges related to targeting this molecular for therapy, with an attempt to provide directions for subsequent studies.

show abstract

Section: Tigit Expression In Autoimmune Diseasesmentioning

confidence: 99%

The landscape of TIGIT target and clinical application in diseases

et al. 2022

View full text Add to dashboard Cite

show abstract

“…cDNA Synthesis and RT-qPCR Experiments cDNA synthesis was accomplished with the PrimeScript ™ RT Reagent kit (Takara Bio, USA) using 100 ng of total RNA input in a 40 ml final mastermix reaction, as previously described (39) Quantity and purity of RNA samples were initially verified by OD 260 /OD 280 ratio > 1.8. using IMPLEN NanoPhotometer P-Class P-330 (IMPLEN GmbH, Germany). Obtained cDNA samples were diluted 6-fold and used as a template for subsequent quantitative real-time PCR analysis of eight selected targets (PLZF/ZBTB16, RUNX3, RORC, TBX21, EOMES, IL-18R, CCR6, CCR10) and two reference genes (ACTB and TBP) using QuantStudio 5 instrument (Thermo Fisher Scientific, USA).…”

Section: Flow Cytometry Analysis Of Peripheral Mr1-restricted and Gdtmentioning

confidence: 99%

Differential Skewing of Circulating MR1-Restricted and γδ T Cells in Human Psoriasis Vulgaris

et al. 2020

Self Cite

View full text Add to dashboard Cite

Psoriasis vulgaris (PV) is a chronic, recurrent inflammatory dermatosis mediated by aberrantly activated immune cells. The role of the innate-like T cells, particularly gammadelta T (γδT) cells and MR1-restricted T lymphocytes, is incompletely explored, mainly through animal models, or by use of surrogate lineage markers, respectively. Here, we used case-control settings, multiparameter flow cytometry, 5-OP-RU-loaded MR1-tetramers, Luminex technology and targeted qRT-PCR to dissect the cellular and transcriptional landscape of γδ and MR1-restricted blood T cells in untreated PV cases (n=21, 22 matched controls). High interpersonal differences in cell composition were observed, fueling transcriptional variability at healthy baseline. A minor subset of canonical CD4+CD8+MR1-tet+TCRVα7.2+ and CD4+CD8-MR1-tet+TCRVα7.2+ T cells was the most significantly underrepresented community in male PV individuals, whereas Vδ2+ γδ T cells expressing high levels of TCR and Vδ1-δ2- γδ T cells expressing intermediate levels of TCR were selectively enriched in affected males, partly reflecting disease severity. Our findings highlight a formerly unappreciated skewing of human circulating MAIT and γδ cytomes during PV, and reveal their compositional changes in relation to sex, CMV exposure, serum cytokine content, BMI, and inflammatory burden. Complementing numerical alterations, we finally show that flow-sorted, MAIT and γδ populations exhibit divergent transcriptional changes in mild type I psoriasis, consisting of differential bulk expression for signatures of cytotoxicity/type-1 immunity (EOMES, RUNX3, IL18R), type-3 immunity (RORC, CCR6), and T cell innateness (ZBTB16).

show abstract